+

WO2007016380A3 - Cyclitol linker polymer conjugate - Google Patents

Cyclitol linker polymer conjugate Download PDF

Info

Publication number
WO2007016380A3
WO2007016380A3 PCT/US2006/029503 US2006029503W WO2007016380A3 WO 2007016380 A3 WO2007016380 A3 WO 2007016380A3 US 2006029503 W US2006029503 W US 2006029503W WO 2007016380 A3 WO2007016380 A3 WO 2007016380A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclitol
polymer
biologically active
polymer conjugate
linker polymer
Prior art date
Application number
PCT/US2006/029503
Other languages
French (fr)
Other versions
WO2007016380A2 (en
Inventor
David I Turner
Perry Calias
Gary P Cook
David T Shima
Original Assignee
Osi Eyetech Inc
David I Turner
Perry Calias
Gary P Cook
David T Shima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Eyetech Inc, David I Turner, Perry Calias, Gary P Cook, David T Shima filed Critical Osi Eyetech Inc
Priority to JP2008524213A priority Critical patent/JP2009510182A/en
Priority to EP06800487A priority patent/EP1912676A2/en
Publication of WO2007016380A2 publication Critical patent/WO2007016380A2/en
Publication of WO2007016380A3 publication Critical patent/WO2007016380A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Conjugating biologically active molecules with polymers, high molecular weight non- immunogenic and lipophilic compounds has been described to improve in vivo profiles of the biologically active molecules. The invention relates to a conjugate comprising a polymer, a biologically active molecule and cyclitol linking the polymer to the biologically active molecule. The invention also relates to an activated polymer composition comprising a polymer, an active functional group and a cyclitol linking the polymer to the active functional group.
PCT/US2006/029503 2005-07-28 2006-07-27 Cyclitol linker polymer conjugate WO2007016380A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008524213A JP2009510182A (en) 2005-07-28 2006-07-27 Cycitol linker polymer conjugate
EP06800487A EP1912676A2 (en) 2005-07-28 2006-07-27 Cyclitol linker polymer conjugate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70313305P 2005-07-28 2005-07-28
US60/703,133 2005-07-28

Publications (2)

Publication Number Publication Date
WO2007016380A2 WO2007016380A2 (en) 2007-02-08
WO2007016380A3 true WO2007016380A3 (en) 2007-08-16

Family

ID=37451164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029503 WO2007016380A2 (en) 2005-07-28 2006-07-27 Cyclitol linker polymer conjugate

Country Status (3)

Country Link
EP (1) EP1912676A2 (en)
JP (1) JP2009510182A (en)
WO (1) WO2007016380A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US9566242B2 (en) 2010-02-25 2017-02-14 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011055751A (en) * 2009-09-09 2011-03-24 Tokyo Univ Of Agriculture & Technology Method for preparing dendrimer-modified magnetic fine particle
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
RU2598627C2 (en) 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Composition based on nanoparticles with improved penetration through mucous membranes
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
AU2013232300B2 (en) * 2012-03-16 2015-12-17 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
JP6392209B2 (en) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Lipid-based drug carriers for rapid permeation through the mucus lining
DK2906246T3 (en) 2012-10-11 2023-09-04 Ascendis Pharma Ophthalmology Div A/S VEGF-Neutralizing Prodrugs Including Ranibizumab for the Treatment of Ocular Conditions Characterized by Ocular Neovascularization
CN103830741B (en) * 2012-11-27 2019-02-19 杨子剑 Compound and preparation method and purposes containing tazatide analog structure
CN103848901A (en) * 2012-11-28 2014-06-11 杨子剑 New compound containing vancomycin structure as well as preparation method and application thereof
CN103848894A (en) * 2012-11-30 2014-06-11 杨子剑 Novel compound containing daptomycin structure as well as preparation method and application thereof
CN103897041A (en) * 2012-12-24 2014-07-02 杨子剑 Novel compound containing vancomycin structure and preparation method and use thereof
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
JP6633537B2 (en) * 2014-10-22 2020-01-22 スガイ化学工業株式会社 Method for producing decalin derivative
JP6846351B2 (en) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー Hypotonic hydrogel formulation for enhanced transport of active agents on mucosal surfaces

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
WO1998018480A1 (en) * 1996-10-25 1998-05-07 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
WO2004092191A2 (en) * 2003-04-13 2004-10-28 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
WO2005110489A2 (en) * 2004-04-13 2005-11-24 (Osi) Eyetech, Inc. Nucleic acid aptamers conjugated to high molecular weight steric groups

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020159951A1 (en) * 1997-05-06 2002-10-31 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
PT1397155E (en) * 2001-06-21 2015-12-07 Genentech Inc Sustained release formulation
CA2528001A1 (en) * 2003-04-04 2004-10-21 The University Of Tokyo Lipid membrane structure containing anti-mt-mmp monoclonal antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
WO1998018480A1 (en) * 1996-10-25 1998-05-07 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
WO2004092191A2 (en) * 2003-04-13 2004-10-28 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
WO2005110489A2 (en) * 2004-04-13 2005-11-24 (Osi) Eyetech, Inc. Nucleic acid aptamers conjugated to high molecular weight steric groups

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NICKLAUS M C ET AL: "HIV-1 INTEGRASE PHARMACOPHORE: DISCOVERY OF INHIBITORS THROUGH THREE-DIMENSIONAL DATABASE SEARCHING", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 6, 14 March 1997 (1997-03-14), pages 920 - 929, XP000978721, ISSN: 0022-2623 *
See also references of EP1912676A2 *
STADELMAIER, ANDREAS ET AL: "Synthesis of serine-linked phosphatidylinositol mannosides (PIMs)", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY ( 2004 ), (15), 3292-3303 CODEN: EJOCFK; ISSN: 1434-193X, 2004, XP002419500 *
STETSENKO D A ET AL: "EFFICIENT CONJUGATION OF PEPTIDES TO OLIGONUCLEOTIDES BY NATIVE LIGATION", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 65, 2000, pages 4900 - 4908, XP000992973, ISSN: 0022-3263 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9566242B2 (en) 2010-02-25 2017-02-14 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers

Also Published As

Publication number Publication date
WO2007016380A2 (en) 2007-02-08
EP1912676A2 (en) 2008-04-23
JP2009510182A (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2007016380A3 (en) Cyclitol linker polymer conjugate
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
WO2006124737A3 (en) Molecular constructs suitable for targeted conjugates
EP2279758A3 (en) Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2008069824A3 (en) Compositions and methods for transport of molecules with enhanced release properties across biological barriers
EP2537533A3 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
EP2626080A3 (en) Conjugated factor VIII molecules
WO2009016516A3 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
IL189187A (en) Polymer conjugates of k-252a and derivatives thereof, pharmaceutical compositions comprising the same and uses thereof
WO2004110358A3 (en) Polymeric conjugates for tissue activated drug delivery
WO2005014024A3 (en) Conjugates of a polymer and a protein linked by an oxime linking group
WO2007054468A3 (en) Preparation of functionalized cationic polymers and their preparation and application in personal care
EP2468304A3 (en) Process for preparing stable drug conjugates
MX2008002597A (en) Process for preparing purified drug conjugates.
WO2008077956A3 (en) Oligonucleotide-, protein and/or peptide-polymer conjugates
WO2010006282A3 (en) Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
WO2010014708A3 (en) Factor viii polymer conjugates
CU23556A1 (en) POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
MXPA05002444A (en) Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto.
WO2007019331A3 (en) Conjugates of a g-csf moiety and a polymer
WO2009089542A3 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
WO2009001364A3 (en) Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
WO2006108673A3 (en) Low amounts of high molecular weight polymers for enhancing viscosity of aqueous/aqueous biphasic liquids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008524213

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006800487

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载